Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 14, 2024; 30(30): 3541-3547
Published online Aug 14, 2024. doi: 10.3748/wjg.v30.i30.3541
Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease
Maurizio Soresi, Lydia Giannitrapani
Maurizio Soresi, Lydia Giannitrapani, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo 90127, Italy
Author contributions: Soresi M and Giannitrapani L contributed to this paper; Soresi M designed the overall manuscript concept and outline; Giannitrapani L contributed to manuscript discussion and design; Soresi M and Giannitrapani L contributed to the writing, and editing of the manuscript, illustrations, literature review, and read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Maurizio Soresi, MD, Associate Professor, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Via del Vespro 141, Palermo 90127, Italy. maurizio.soresi@unipa.it
Received: January 26, 2024
Revised: June 26, 2024
Accepted: July 18, 2024
Published online: August 14, 2024
Processing time: 195 Days and 16.1 Hours
Core Tip

Core Tip: In this editorial, we comment on Yin et al’s recently published Letter to the editor. Despite the widespread diffusion, up to now there have been no drugs capable of reliably blocking the evolution of non-alcoholic steato-hepatitis towards advanced stages of fibrosis. We agree with Yin et al that glucagon-like peptide receptor agonists monotherapy does not perform well as an antifibrotic therapy. The use of combination therapy according to disease stage and co-morbidities, will also be a challenge in the near future.